MBX BIOSCIENCES INC (MBX)
Health Care · Clinical-stage biopharmaceuticals / drug development platforms · NASDAQ
A clinical-stage biopharmaceutical company leveraging a proprietary platform to optimize drug candidate properties and develop therapies across multiple indications.
What MBX BIOSCIENCES INC does
MBX Biosciences is a clinical-stage biopharmaceutical company that develops drug candidates through its proprietary platform designed to optimize pharmacokinetic and pharmacologic properties. The company focuses on advancing multiple product candidates through preclinical studies and clinical trials, with capabilities in discovery, development, and manufacturing to address unmet medical needs across various therapeutic areas.
Themes: ["drug discovery and development","clinical-stage therapeutics","platform technology"]
Fundamentals
- Price$65.71 as of 2026-07-09 close
- Market cap$2.9B as of 2026-07-10
- 1-year return+372.4% as of 2026-07-09 close
- ROE-24.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.54 as of 2026-07-10
Key risks (from latest filing)
["Inability to successfully complete clinical trials or achieve safety and efficacy outcomes for product candidates could prevent regulatory approval and commercialization","Reliance on third parties to conduct clinical trials and manufacture product candidates creates execution and supply chain risks","Clinical development, regulatory approval, and commercialization activities require substantial capital and the company will need additional financing to fund operations and development programs"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.